We are live on ! Find out more
ATYR

aTyr Pharma
ATYR

24 hedge funds and large institutions have $14.7M invested in aTyr Pharma in 2020 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 3

83% more capital invested

Capital invested by funds: $8.02M → $14.7M (+$6.66M)

41% more funds holding

Funds holding: 17 → 24 (+7)

6.63% more ownership

Funds ownership: 49.46% → 56.1% (+6.6%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
24
Holders Change
+7
Holders Change %
+41.18%
% of All Funds
0.53%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
7
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Federated Hermes
Federated Hermes
Pennsylvania
+$4.4M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$3.93M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$3.19M
4
Viking Global Investors
Viking Global Investors
Connecticut
+$1.55M
5
Two Sigma Investments
Two Sigma Investments
New York
+$277K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$8K

ATYR Hedge Fund Activity: Q1 2020 in Review

24 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q1 2020, worth a combined $14.7M — up 83% from $8.02M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new ATYR positions and 3 closed out — a net gain of 8 holders — while 7 added to existing stakes and 0 trimmed.

The largest buyer was Federated Hermes, adding an estimated $4.4M. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $8K sold.

  • 24 institutional investors held aTyr Pharma (ATYR) as of Q1 2020, up from 17 in Q4 2019.
  • Funds reported $14.7M of aTyr Pharma stock for Q1 2020, up 83% quarter-over-quarter.
  • 11 funds opened new aTyr Pharma positions in Q1 2020 and 3 closed out, a net change of +8 holders.
  • The largest aTyr Pharma buyer in Q1 2020 was Federated Hermes, an estimated $4.4M added.
  • The largest aTyr Pharma seller in Q1 2020 was Tower Research Capital (TRC), an estimated $8K sold.

Based on aggregated 13F filings for Q1 2020.